

Ravichandran Ramasamy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2156459/publications.pdf>

Version: 2024-02-01

57
papers

4,460
citations

201674

27
h-index

168389

53
g-index

58
all docs

58
docs citations

58
times ranked

6105
citing authors

#	ARTICLE	IF	CITATIONS
1	The RAGE/DIAPH1 Signaling Axis & Implications for the Pathogenesis of Diabetic Complications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4579.	4.1	12
2	Inflammation Meets Metabolism Roles: for the Receptor for Advanced Glycation End Products Axis in Cardiovascular Disease. <i>Immunometabolism</i> , 2021, 3, .	1.6	12
3	Heme & RAGE: A new opportunistic relationship?. <i>FEBS Journal</i> , 2021, 288, 3424-3427.	4.7	3
4	Aldose Reductase: An Emerging Target for Development of Interventions for Diabetic Cardiovascular Complications. <i>Frontiers in Endocrinology</i> , 2021, 12, 636267.	3.5	47
5	Diabetes and Cardiovascular Complications: The Epidemics Continue. <i>Current Cardiology Reports</i> , 2021, 23, 74.	2.9	6
6	Macrophage-adipocyte communication and cardiac remodeling. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	3
7	Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice. <i>Science Translational Medicine</i> , 2021, 13, eabf7084.	12.4	28
8	Advanced Glycation End Products: Building on the Concept of the “Common Soil” in Metabolic Disease. <i>Endocrinology</i> , 2020, 161, .	2.8	104
9	An Eclectic Cast of Cellular Actors Orchestrates Innate Immune Responses in the Mechanisms Driving Obesity and Metabolic Perturbation. <i>Circulation Research</i> , 2020, 126, 1565-1589.	4.5	13
10	Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 37.	2.4	134
11	RAGE impairs murine diabetic atherosclerosis regression and implicates IRF7 in macrophage inflammation and cholesterol metabolism. <i>JCI Insight</i> , 2020, 5, .	5.0	38
12	Incense Burning is Associated with Human Oral Microbiota Composition. <i>Scientific Reports</i> , 2019, 9, 10039.	3.3	12
13	A Receptor of the Immunoglobulin Superfamily Regulates Adaptive Thermogenesis. <i>Cell Reports</i> , 2019, 28, 773-791.e7.	6.4	35
14	Metabolism, Obesity, and Diabetes Mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, e166-e174.	2.4	15
15	Preclinical and Clinical Proof of Concept for Metabolic Intervention in Diabetic Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2019, 25, S77.	1.7	1
16	Significance and Mechanistic Relevance of SIRT6-Mediated Endothelial Dysfunction in Cardiovascular Disease Progression. <i>Circulation Research</i> , 2019, 124, 1408-1410.	4.5	16
17	Metabolic dysfunction in Emirati subjects in Abu Dhabi: Relationship to levels of soluble RAGEs. <i>Journal of Clinical and Translational Endocrinology</i> , 2019, 16, 100192.	1.4	2
18	The Receptor for Advanced Glycation End Products (RAGE) and DIAPH1: Implications for vascular and neuroinflammatory dysfunction in disorders of the central nervous system. <i>Neurochemistry International</i> , 2019, 126, 154-164.	3.8	44

#	ARTICLE	IF	CITATIONS
19	The receptor for advanced glycation end products (RAGE) and DIAPH1: unique mechanisms and healing the wounded vascular system. <i>Expert Review of Proteomics</i> , 2019, 16, 471-474.	3.0	6
20	Netrin-1 Alters Adipose Tissue Macrophage Fate and Function in Obesity. <i>Immunometabolism</i> , 2019, 1, .	1.6	41
21	Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study. <i>Scientific Reports</i> , 2018, 8, 11327.	3.3	51
22	The UAE healthy future study: a pilot for a prospective cohort study of 20,000 United Arab Emirates nationals. <i>BMC Public Health</i> , 2018, 18, 101.	2.9	32
23	Deletion of the formin <i>Diaph1</i> protects from structural and functional abnormalities in the murine diabetic kidney. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1601-F1612.	2.7	18
24	Human Aldose Reductase Expression Prevents Atherosclerosis Regression in Diabetic Mice. <i>Diabetes</i> , 2018, 67, 1880-1891.	0.6	18
25	Patterns of tobacco use in the United Arab Emirates Healthy Future (UAEHFS) pilot study. <i>PLoS ONE</i> , 2018, 13, e0198119.	2.5	32
26	Training scientists as future industry leaders: teaching translational science from an industry executive's perspective. <i>Journal of Translational Science</i> , 2018, 4, .	0.2	1
27	Targeted drug discovery and development, from molecular signaling to the global market: an educational program at New York University, 5-year metrics. <i>Journal of Translational Science</i> , 2018, 4, 1-9.	0.2	21
28	Small Molecule Antagonists of RAGE-DIAPH1: Novel Therapeutic Opportunities in Metabolic and Chronic Disease. <i>FASEB Journal</i> , 2018, 32, 603.4.	0.5	0
29	Glycation & the RAGE axis: targeting signal transduction through DIAPH1. <i>Expert Review of Proteomics</i> , 2017, 14, 147-156.	3.0	25
30	The Formin, DIAPH1, is a Key Modulator of Myocardial Ischemia/Reperfusion Injury. <i>EBioMedicine</i> , 2017, 26, 165-174.	6.1	25
31	Aldose reductase modulates acute activation of mesenchymal markers via the β -catenin pathway during cardiac ischemia-reperfusion. <i>PLoS ONE</i> , 2017, 12, e0188981.	2.5	3
32	Small Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 Signal Transduction. <i>Scientific Reports</i> , 2016, 6, 22450.	3.3	79
33	Aldose Reductase Acts as a Selective Derepressor of PPAR β and the Retinoic Acid Receptor. <i>Cell Reports</i> , 2016, 15, 181-196.	6.4	23
34	Cellular mechanisms and consequences of glycation in atherosclerosis and obesity. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 2244-2252.	3.8	56
35	Mechanisms of transcription factor acetylation and consequences in hearts. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 2221-2231.	3.8	28
36	Cardiovascular K ⁺ ATP channels and advanced aging. <i>Pathobiology of Aging & Age Related Diseases</i> , 2016, 6, 32517.	1.1	9

#	ARTICLE	IF	CITATIONS
37	The multiple faces of RAGE – opportunities for therapeutic intervention in aging and chronic disease. Expert Opinion on Therapeutic Targets, 2016, 20, 431-446.	3.4	83
38	Acute Administration of n-3 Rich Triglyceride Emulsions Provides Cardioprotection in Murine Models after Ischemia-Reperfusion. PLoS ONE, 2015, 10, e0116274.	2.5	17
39	Glutaminolysis and Transferrin Regulate Ferroptosis. Molecular Cell, 2015, 59, 298-308.	9.7	1,252
40	RAGE Suppresses ABCG1-Mediated Macrophage Cholesterol Efflux in Diabetes. Diabetes, 2015, 64, 4046-4060.	0.6	54
41	Deletion of mDia1 is Protective Against Renal Damage in a Murine Model of Diabetes. FASEB Journal, 2015, 29, LB763.	0.5	0
42	Unlocking the biology of RAGE in diabetic microvascular complications. Trends in Endocrinology and Metabolism, 2014, 25, 15-22.	7.1	164
43	RAGE Regulates the Metabolic and Inflammatory Response to High-Fat Feeding in Mice. Diabetes, 2014, 63, 1948-1965.	0.6	168
44	Acute Administration of n-3 Triglyceride Emulsion Provides Marked Cardioprotection After Ischemia/Reperfusion. FASEB Journal, 2013, 27, 359.6.	0.5	0
45	Aldose reductase modulates cardiac glycogen synthase kinase-3 β phosphorylation during ischemia-reperfusion. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 303, H297-H308.	3.2	18
46	Formin mDia1 Mediates Vascular Remodeling via Integration of Oxidative and Signal Transduction Pathways. Circulation Research, 2012, 110, 1279-1293.	4.5	78
47	Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. Journal of Experimental Medicine, 2012, 209, 2339-2350.	8.5	95
48	The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascular Pharmacology, 2012, 57, 160-167.	2.1	134
49	Receptor for Advanced Glycation End Products (RAGE) and Implications for the Pathophysiology of Heart Failure. Current Heart Failure Reports, 2012, 9, 107-116.	3.3	66
50	Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Annals of the New York Academy of Sciences, 2011, 1243, 88-102.	3.8	387
51	Deletion of the Receptor for Advanced Glycation End Products Reduces Glomerulosclerosis and Preserves Renal Function in the Diabetic OVE26 Mouse. Diabetes, 2010, 59, 2043-2054.	0.6	151
52	Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondrial permeability transition pore. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 296, H333-H341.	3.2	43
53	RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H1823-H1832.	3.2	121
54	RAGE and Modulation of Ischemic Injury in the Diabetic Myocardium. Diabetes, 2008, 57, 1941-1951.	0.6	100

#	ARTICLE	IF	CITATIONS
55	Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE ^{-/-} mice. Journal of Clinical Investigation, 2008, 118, 183-194.	8.2	325
56	Receptor for Advanced-Glycation End Products. Circulation, 2006, 113, 1226-1234.	1.6	203
57	Glycation and a Spark of ALEs (Advanced Lipoxidation End Products) Igniting RAGE/Diaphanous-1 and Cardiometabolic Disease. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	8